<DOC>
	<DOCNO>NCT01961882</DOCNO>
	<brief_summary>To compare disease-free survival patient 60 year old acute myeloid leukemia ( AML ) randomly assign receive either OCV-501 monotherapy placebo .</brief_summary>
	<brief_title>A Phase 2 Trial Evaluate Efficacy Safety OCV-501 Elderly Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients AML achieve first complete remission within one two course standard induction therapy , complete standard consolidation therapy ( one course ) . Patients 60 year old . Patients provide write informed consent within 90 day last dose consolidation therapy inform consent form approve institutional review board independent ethic committee . Patients acute promyelocytic leukemia ( APL ) ( 15 ; 17 ) ( q22 ; q12 ) , ( PML/RARA ) karyotype abnormality , variant type . Patients schedule hematopoietic stem cell transplantation . Patients receive drug potentially affect immune system within 4 week start IMP administration may receive drug start trial . Patients severe concurrent disease psychiatric illness likely interfere participation trial . Patients HIV antibody positive , HBVDNA positive unrecovered chronic hepatitis C positive HCV antibody . Patients cirrhosis . Patients judge ineligible investigator ( subinvestigator ) reason .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>OCV-501</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Antigen specific cancer immunotherapeutic</keyword>
</DOC>